Efficacy and Safety of AlbisD Compared With Omeprazole 20 mg in Patients With Non-erosive Reflux Disease: A Randomized, Open-label, Active-controlled, Pilot Study.
Conclusions: The efficacy and safety of AlibsD in treating NERD patients are not inferior to those of omeprazole. Therefore, AlbisD can be an alternative to PPIs for NERD. PMID: 31327222 [PubMed]
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 35-year-old man is evaluated during a follow-up appointment for persistent heartburn with chronic cough. He has a 1-year history of gastroesophageal reflux disease and takes pantoprazole twice daily. He reports no nausea, vomiting, or dysphagia. Upper endoscopy performed 1 year […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
This article reviews the current literature regarding established and proposed EE-GERD, reporting on all available options for its correct diagnosis and therapeutic management. Expert opinion: MII-pH could help to identify a hidden GERD that causes EE. Unfortunately, standard MII-pH analysis results are often unable to define this association. New parameters such as the mean nocturnal baseline impedance and post-reflux swallow-induced peristaltic wave index may have an improved diagnostic yield, but prospective studies using impedance-pH are needed. PMID: 31322443 [PubMed - as supplied by publisher]
ConclusionsGEJ opening dynamics attained by EndoFLIP appear to be associated with symptomatic outcomes. When the Dmin and CSA do not decrease by a defined threshold, heartburn is more likely to be severe at 6 or more months postoperatively. This suggests that the fundoplication may not be tight enough to prevent persistent or recurrent GERD.
CONCLUSION: The majority of GPs and otolaryngologists do not believe themselves to be sufficiently informed about LPR, leading to different practice patterns and grey areas. The elaboration of international recommendations in the management of reflux is needed to improve practices. PMID: 31257901 [PubMed - as supplied by publisher]
CONCLUSION: The QoLRAD test measuring quality of life, except some subdomains in our study that we performed on patients diagnosed with GERD, was found to be valid and reliable. PMID: 31144656 [PubMed - in process]
CONCLUSION Male gender and hiatal hernia were associated with EE. Aged patients, smoking and hiatal herni a were related to severe EE. It is suggested that the risk factors for EE and non-EE types are different. Cohort studies are necessary to identify the exact mechanisms involved in each disease form.RESUMO CONTEXTO: A doen ça do refluxo gastroesofágico (DRGE) é uma das doenças digestivas mais comuns na prática médica e deve ser suspeitada de acordo com os seus sintomas clínicos, podendo ser classificada em esofagite erosiva (EE) de acordo com os achados de endoscopia. OBJ...
Conclusions Transoral incisionless fundoplication with EsophyX is an effective therapeutic option for symptomatic gastroesophageal reflux disease patients, with Hill grades I – II or hiatal hernia
Gastro-oesophageal reflux disease (GORD) is a common disorder with an increasing prevalence in th UK. The presence of a hiatus hernia is the strongest risk factor for developing GORD, although not essential. The most common symptoms experienced by patients with GORD are heartburn and acid regurgitation. Diagnosis of GORD is usually made from the clinical history. Endoscopy and ambulatory pH monitoring are adjunctive tests that can influence management decisions. The main goals of treatment are symptom control and the prevention of complications such as Barrett's oesophagus and peptic stricture.
CONCLUSIONS: These data showed that GERD is present in a quarter of ABG patients, suggesting that hypochlorhydria not exclude per se arising of oesophageal symptoms. In ABG we found that ME is a frequent finding but its clinical relevance remains to be investigated with further studies. PMID: 30638085 [PubMed - as supplied by publisher]
Heartburn and regurgitation are the primary “typical” symptoms of GERD.1 Proton pump inhibitor (PPI) therapy controls heartburn in the vast majority of patients and improves regurgitation in many, but certainly not all, patients. Dysfunction of the lower esophageal sphincter (either hypotension or transient relaxation) often combined with weakness in esophageal acid clearance is the underlying pathophysiology of reflux disease, so refractory regurgitation is not surprising because acid blockers neutralize the gastric contents but do not actually change the underlying motility deficits.